Botanix Pharmaceuticals LimitedASX: BOT

FDA Approves Sofdra

· Issued by Botanix Pharmaceuticals Limited

Filed with ASX · · 4 pages · English

Summary by 6ix AI

Botanix Pharmaceuticals Limited has announced the FDA approval of Sofdra, a new topical gel for treating primary axillary hyperhidrosis, which is excessive underarm sweating. The company plans to launch a patient experience program in the third quarter of the year, with expectations for initial revenue from Sofdra in the fourth quarter.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Botanix Pharmaceuticals Limited on 6ix

Earlier from Botanix Pharmaceuticals

Later from Botanix Pharmaceuticals

All Botanix Pharmaceuticals news releases